Aurinia Pharmaceuticals announced that the Patent Trial and Appeal Board of the United States’ Patent and Trademark Office has terminated the Inter Partes Review it had instituted with respect to Aurinia’s U.S. Patent No. 10,286,036.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AUPH:
- Aurinia announces allowance of new, refined method of use patent for LUPKYNIS
- Aurinia Pharmaceuticals call volume above normal and directionally bullish
- Aurinia Pharmaceuticals backs FY23 net product revenue view $120M-$140M
- Aurinia Pharmaceuticals reports preliminary net FY22 revenue $134M
- Aurinia Pharmaceuticals reports preliminary Q4 revenue $28.4M, consensus $26.97M
Questions or Comments about the article? Write to editor@tipranks.com